Erratum: "In Vitro evaluation of allergen potencies of commercial house dust mite sublingual immunotherapy reagents" [Allergy Asthma Immunol Res. (2015), 7(2): (124-129)] Doi:10.4168/aair.2015.7.2.124;In Vitro evaluation of allergen potencies of commercial house dust mite sublingual immunotherapy reagents

Allergy, Asthma and Immunology Research

Volumn 7, Issue 2, 2014, Pages 124-129

  Park, Kyung Hee ^a   Son, Mina ^a   Choi, Soo Young ^a   Park, Hey Jung ^a   Lee, Jae Hyun ^a   Jeong, Kyoung Yong ^a   Lee, Joo Shil ^b   Park, Jung Won ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Korea National Institute of Health   (South Korea)

Author keywords

House dust mite; Standardization; Sublingual immunotherapy

Indexed keywords

HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; IMMUNOMODULATING AGENT;

ALLERGY RAPID TEST; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DERMATOPHAGOIDES; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DRUG POTENCY; DRUG SCREENING; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IN VITRO STUDY; MAINTENANCE DRUG DOSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; STANDARD; SUBLINGUAL IMMUNOTHERAPY;

EID: 84937862115     PISSN: 20927355     EISSN: 20927363     Source Type: Journal    
DOI: 10.4168/aair.2017.9.2.187     Document Type: Erratum

References (25)

1. Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 2011;66:740-52.
2. Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy 2009;64:1570-9.
3. Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009;64 Suppl 91:1-59.
4. Hur GY, Kim TB, Han MY, Nahm DH, Park JW; Allergen and Immunotherapy Work Group of the Korean Academy of Asthma, Allergy and Clinical Immunology (KAAACI). A survey of the prescription patterns of allergen immunotherapy in Korea. Allergy Asthma Immunol Res 2013;5:277-82.
5. Calderón MA, Simons FE, Malling HJ, Lockey RF, Moingeon P, Demoly P. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 2012;67:302-11.
6. Norman PS. An overview of immunotherapy: implications for the future. J Allergy Clin Immunol 1980;65:87-96.
7. Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol 2007;120:S25-85.
8. Ewbank PA, Murray J, Sanders K, Curran-Everett D, Dreskin S, Nelson HS. A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract. J Allergy Clin Immunol 2003;111:155-61.
9. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:802-9.
10. Didier A, Malling HJ, Worm M, Horak F, Jäger S, Montagut A, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:1338-45.
11. Bousquet J, Bieber T, Fokkens W, Humbert M, Kowalski ML, Niggemann B, et al. Consensus statements, evidence-based medicine and guidelines in allergic diseases. Allergy 2008;63:1-4.
12. Mösges R, Pasch N, Schlierenkämper U, Lehmacher W. Comparison of the biological activity of the most common sublingual allergen solutions made by two European manufacturers. Int Arch Allergy Immunol 2006;139:325-9.
13. Larenas-Linnemann D, Esch R, Plunkett G, Brown S, Maddox D, Barnes C, et al. Maintenance dosing for sublingual immunotherapy by prominent European allergen manufacturers expressed in bioequivalent allergy units. Ann Allergy Asthma Immunol 2011;107:448-58.e3.
14. Cox L, Jacobsen L. Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann Allergy Asthma Immunol 2009;103:451-59.
15. Larenas-Linnemann D, Cox LS; Immunotherapy and Allergy Diagnostics Committee of the American Academy of Allergy, Asthma and Immunology. European allergen extract units and potency: review of available information. Ann Allergy Asthma Immunol 2008; 100:137-45.
16. Bush RK, Swenson C, Fahlberg B, Evans MD, Esch R, Morris M, et al. House dust mite sublingual immunotherapy: results of a US trial. J Allergy Clin Immunol 2011;127:974-81.e1-7.
17. Slater JE, Pastor RW. The determination of equivalent doses of standardized allergen vaccines. J Allergy Clin Immunol 2000; 105:468-74.
18. Cox L, Esch RE, Corbett M, Hankin C, Nelson M, Plunkett G. Allergen immunotherapy practice in the United States: guidelines, measures, and outcomes. Ann Allergy Asthma Immunol 2011;107: 289-99.
19. Francis JN, Durham SR. Adjuvants for allergen immunotherapy: experimental results and clinical perspectives. Curr Opin Allergy Clin Immunol 2004;4:543-8.
20. van Ree R. Indoor allergens: relevance of major allergen measurements and standardization. J Allergy Clin Immunol 2007;119:270-7.
21. Jeong KY, Hong CS, Lee JS, Park JW. Optimization of allergen standardization. Yonsei Med J 2011;52:393-400.
22. Park JW, Kim KS, Jin HS, Kim CW, Kang DB, Choi SY, et al. Der p 2 isoallergens have different allergenicity, and quantification with 2-site ELISA using monoclonal antibodies is influenced by the isoallergens. Clin Exp Allergy 2002;32:1042-7.
23. van Ree R, Chapman MD, Ferreira F, Vieths S, Bryan D, Cromwell O, et al. The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy 2008;63:310-26.
24. Chapman MD, Ferreira F, Villalba M, Cromwell O, Bryan D, Becker WM, et al. The European Union CREATE project: a model for international standardization of allergy diagnostics and vaccines. J Allergy Clin Immunol 2008;122:882-9.e2.
25. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998;102:558-62.